Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Account Payables
Amounts the company owes suppliers for goods and services received.
Helix BioPharma Corp.TSX: HBP.TO
Account Payables · Q3 FY2026 · quarter ended Apr 2026
Account payables rises 40.5% from a year ago
Account payables stood at CA$2.5M at the end of Q3 FY2026, up 40.5% from a year earlier and up 1.3% from the prior quarter.
Context
- Account payables amounted to 11.7% of total assets at the end of Q3 FY2026, down 164.9 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +40.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
CAD · from the balance sheet
- Latest · FY2025
- 0 CAD
- Year-over-year change
- -100.0%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 0 | -100.0% |
| FY2024 | 2024-07-31 | 855K | +73.4% |
| FY2023 | 2023-07-31 | 493K | -17.7% |
| FY2022 | 2022-07-31 | 599K | -59.1% |
| FY2021 | 2021-07-31 | 1.47M | — |
Account Payables vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +40.5% is the highest of 4, against a peer median of +12.0%.
- Account payables amounts to 11.7% of total assets for HBP.TO, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $9.93M USD | +14.4% | -3.5% | 7.6% | |
| Apr 2026 | CA$2.5M CAD | +40.5% | — | 11.7% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $2.11M USD | +12.0% | +6.5% | 2.8% |
| Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| Apr 2026 | CA$0 CAD | — | — | 0.0% | |
| Peer median (excluding HBP.TO) | — | +12.0% | +1.5% | 1.4% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.